-transparent.png){kind=logo}
A complete remission rate of 82% was obtained in a group of 68 patients with acute myelogenous leukemia treated with a high-dose induction chemotherapy (TAD) consisting of 7-day courses of 6-thioguanine, cytarabine, and daunorubicin. The patients who achieved remission received intensive consolidation chemotherapy and were randomized to receive maintenance chemotherapy with or without immunotherapy. Median remission duration was 13 months and median survival, 21 months. Neither central nervous system prophylaxis nor the addition of immunotherapy to the maintenance regimen prolonged remissions or improved survival. Age, sex, and subclassification of acute myelogenous leukemia had no effect on the remission rate or survival. These data indicate that a large proportion of patients with acute myelogenous leukemia can achieve remission with intensive induction chemotherapy. Attempts to prolong remission have been less successful.
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
January 1990,
Haematology and blood transfusion,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
January 2001,
Advances in therapy,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
January 2005,
Current hematology reports,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
August 1992,
Leukemia,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
November 1989,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
January 1987,
Haematology and blood transfusion,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
November 1980,
Cancer,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
October 1972,
Journal of the Irish Medical Association,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
August 2009,
Anticancer research,
R P Gale, and
K A Foon, and
M J Cline, and
J Zighelboim
December 1985,
Cancer treatment reports,
